Type 2 diabetes and obesity are some of the biggest health challenges in Mainland China. Even though several drug classes have been available to treat these patients, very few have been able to…
The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key NK/T-cell patient populations covering 171 countries and more than 99%…
Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…